348 related articles for article (PubMed ID: 33470281)
1. ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy.
Barroso RMP; Messias K; Garcia DM; Cardillo JA; Scott IU; Messias A; Jorge R
Arq Bras Oftalmol; 2020; 83(6):526-534. PubMed ID: 33470281
[TBL] [Abstract][Full Text] [Related]
2. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
Messias K; Barroso RM; Jorge R; Messias A
Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
[TBL] [Abstract][Full Text] [Related]
3. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation.
Cao G; Xu X; Wang C; Zhang S
Eur J Ophthalmol; 2020 Jan; 30(1):34-39. PubMed ID: 30539668
[TBL] [Abstract][Full Text] [Related]
4. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
[TBL] [Abstract][Full Text] [Related]
5. Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study.
Toscano L; Messias A; Messias K; de Cenço Lopes R; Ribeiro JAS; Scott IU; Jorge R
Doc Ophthalmol; 2021 Dec; 143(3):313-322. PubMed ID: 34347216
[TBL] [Abstract][Full Text] [Related]
6. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.
Messias A; Ramos Filho JA; Messias K; Almeida FP; Costa RA; Scott IU; Gekeler F; Jorge R
Doc Ophthalmol; 2012 Jun; 124(3):225-36. PubMed ID: 22457045
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
Ebneter A; Wolf S; Zinkernagel MS
Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab.
Rentiya ZS; Ferraz DA; Hutnik R; Bae J; Machado CG; Mucciolli C; Motta AALD; Ribeiro LZ; Guan Z; Preti RC; Takahashi WY
Arq Bras Oftalmol; 2022; 85(1):37-45. PubMed ID: 34586227
[TBL] [Abstract][Full Text] [Related]
10. Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy.
Lucena CR; Ramos Filho JA; Messias AM; Silva JA; Almeida FP; Scott IU; Ribeiro JA; Jorge R
Arq Bras Oftalmol; 2013; 76(1):18-20. PubMed ID: 23812521
[TBL] [Abstract][Full Text] [Related]
11. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.
; Googe J; Brucker AJ; Bressler NM; Qin H; Aiello LP; Antoszyk A; Beck RW; Bressler SB; Ferris FL; Glassman AR; Marcus D; Stockdale CR
Retina; 2011 Jun; 31(6):1009-27. PubMed ID: 21394052
[TBL] [Abstract][Full Text] [Related]
14. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
[TBL] [Abstract][Full Text] [Related]
16. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
Mukkamala L; Bhagat N; Zarbin MA
Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069
[TBL] [Abstract][Full Text] [Related]
17. Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.
Zhang W; Zhao G; Fan W; Zhao T
BMC Ophthalmol; 2021 Apr; 21(1):160. PubMed ID: 33789617
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
19. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
[TBL] [Abstract][Full Text] [Related]
20. Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.
Zhou AY; Zhou CJ; Yao J; Quan YL; Ren BC; Wang JM
Int J Ophthalmol; 2016; 9(12):1772-1778. PubMed ID: 28003978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
